Arkolith/Insider Trading/VKTX/Form 4

Zante Greg

Chief Financial OfficerViking Therapeutics, Inc. (VKTX) · full profile →Form 4 · filed Oct 28, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$10.1M
Net Open-Market Flow
-$10.1M
Transactions
16
12 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 28, 2024Option exercise(M)51K$8.52$435K281K
Oct 28, 2024Sell(S)50K$74.56$3.7M231K
Oct 28, 2024Sell(S)19K$75.79$1.4M213K
Oct 28, 2024Sell(S)9K$76.94$713K203K
Oct 28, 2024Sell(S)23K$77.68$1.8M180K
Oct 28, 2024Sell(S)16K$78.69$1.2M165K
Oct 28, 2024Option exercise(M)26K$5.80$151K230K
Oct 28, 2024Sell(S)8K$80.65$643K151K
Oct 28, 2024Sell(S)1K$81.44$98K149K
Oct 28, 2024Sell(S)6K$79.78$483K159K
Oct 28, 2024Option exercise(M)4K$4.68$20K204K
Oct 28, 2024Option exercise(M)13K$7.77$99K200K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 28, 2024Option exercise(M)13K—$00
Oct 28, 2024Option exercise(M)4K—$00
Oct 28, 2024Option exercise(M)26K—$00
Oct 28, 2024Option exercise(M)51K—$0153K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-117885) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML